Melanotan-1 · Research brief

How to Run Melanotan-1 Cycle — Dosing & Safety Protocol

Q: How long does it take to see results from a melanotan-1 cycle?

Visible pigmentation typically appears 10–14 days after beginning the loading phase, with initial color change most noticeable in high-melanocyte-density areas like the face and forearms. Melanogenesis requires melanocyte proliferation, eumelanin synthesis, and melanosome transfer to keratinocytes — processes that take 7–10 days to produce measurable pigment even under optimal dosing and UV coordination. Expecting color change within 3–5 days reflects misunderstanding of melanocyte biology, not peptide inefficacy.

Q: Can I run a melanotan-1 cycle without any UV exposure?

Yes — melanotan-1 stimulates melanogenesis independent of UV exposure by directly activating MC1R receptors on melanocytes. However, coordinated UV exposure 2–4 hours post-injection amplifies melanin production by 30–40% compared to peptide alone, according to photobiology research. UV exposure is optional but produces faster and deeper pigmentation when timed to coincide with peak melanocortin receptor activation.

Q: What happens if I store reconstituted melanotan-1 at room temperature instead of refrigerating it?

Peptide degradation accelerates dramatically above 8°C — a single 24-hour period at room temperature reduces potency by 15–20%, and 72 hours at 20–25°C can degrade over 40% of active peptide. Once reconstituted with bacteriostatic water, melanotan-1 must be stored at 2–8°C to maintain stability. Temperature excursions don’t make the solution unsafe — they render it progressively less effective with each degree above refrigeration range.

Q: How does melanotan-1 compare to melanotan-2 for tanning purposes?

Melanotan-1 exhibits 1,000-fold selectivity for MC1R receptors on melanocytes, producing melanogenesis with minimal systemic effects. Melanotan-2 activates MC1R, MC3R, MC4R, and MC5R broadly — producing faster tanning but also appetite suppression, libido modulation, nausea, and flushing in 40–60% of users. Melanotan-1 requires a longer loading phase but produces equivalent pigmentation with significantly lower side effect incidence.

Q: Is it safe to run melanotan-1 cycles long-term or repeatedly?

Safety data for continuous or repeated melanotan-1 cycles beyond 12 weeks is limited to research contexts — long-term melanocortin receptor modulation effects in humans have not been extensively studied outside clinical trials for erythropoietic protoporphyria. Most research protocols use 8–12 week cycles followed by a washout period to assess baseline pigmentation return. Decisions about cycle duration and frequency should be made in consultation with a qualified healthcare provider familiar with peptide pharmacology.

Q: What should I do if I experience persistent nausea or flushing during a melanotan-1 cycle?

Reduce dose by 0.25mg and extend the interval between injections to allow tolerance development. Nausea and flushing result from off-target MC4R activation in the hypothalamus and typically resolve within 2–3 hours as plasma concentration declines. If symptoms persist beyond 4 hours or worsen with repeated dosing despite dose reduction, discontinue use and consult a healthcare provider — persistent symptoms may indicate individual sensitivity to melanocortin modulation.

Q: Do I need to use bacteriostatic water specifically, or will sterile water work for reconstitution?

Bacteriostatic water is required for multi-dose vials — sterile water lacks preservative and supports bacterial growth if contamination occurs during reconstitution or injection. Bacteriostatic water contains 0.9% benzyl alcohol, which prevents microbial proliferation for 30 days when stored properly. Using sterile water increases contamination risk significantly and shortens solution viability to 48–72 hours.

Q: How much does UV exposure timing matter when running a melanotan-1 cycle?

UV exposure timed 2–4 hours post-injection produces 30–40% greater melanin deposition compared to uncoordinated exposure, according to photobiology research on melanocortin receptor kinetics. Melanotan-1 plasma concentration peaks 60–90 minutes post-injection, but melanocyte MC1R activation persists for 6–8 hours. Scheduling UV during this activation window allows exogenous peptide and UV-induced endogenous alpha-MSH to saturate receptors simultaneously, producing additive melanogenesis.

Q: Can I travel with reconstituted melanotan-1, or does it require continuous refrigeration?

Reconstituted melanotan-1 can tolerate short-term temperature excursions (up to 25°C for 12–24 hours) but potency degrades progressively with each hour above 8°C. For travel, use an insulin cooler or FRIO wallet that maintains 2–8°C without requiring ice or electricity. Lyophilized peptide before reconstitution is stable at room temperature for months, making it more travel-friendly if reconstitution can be performed at the destination.

Q: What is the difference between melanotan-1 and natural alpha-MSH in terms of melanogenesis?

Melanotan-1 (afamelanotide) is a synthetic analogue of alpha-MSH with extended half-life and greater resistance to enzymatic degradation. Natural alpha-MSH has a plasma half-life of 7–10 minutes and requires continuous UV exposure to trigger keratinocyte release, making it impractical for controlled melanogenesis protocols. Melanotan-1’s 33-minute half-life and stable receptor binding allow predictable dosing schedules independent of UV exposure.

Real Peptides Research TeamEditorial

Updated July 9, 202610 min read

60 WORDS

Short answer

A 2018 study published in the Journal of Peptide Science found that improper reconstitution degrades over 40% of melanocortin peptide activity before the first injection. Meaning most cycle failures happen at the preparation stage, not during dosing. The difference between a successful melanotan-1 cycle and a wasted vial comes down to three variables: sterile reconstitution technique, precise dosing escalation, and…

Key takeaways

Melanotan-1 requires a 5–7 day loading phase at 0.25mg daily to saturate melanocyte MC1R receptors before maintenance dosing produces visible melanogenesis.
Reconstitute lyophilized peptide with bacteriostatic water at 1–2mL per 10mg, inject slowly down the vial wall to prevent foam formation, and store at 2–8°C for maximum 30-day viability.
Maintenance dosing of 0.5–1.0mg two to three times weekly sustains melanin production once receptor saturation is achieved. Daily dosing beyond loading phase increases side effects without accelerating tanning.
UV exposure coordinated 2–4 hours post-injection amplifies melanogenesis by 30–40% compared to uncoordinated protocols, but melanotan-1 stimulates melanin synthesis independent of UV exposure.
Side effects (nausea, flushing) result from off-target MC4R activation in the hypothalamus and typically resolve within 2–3 hours. Reducing dose by 0.25mg mitigates symptoms without eliminating melanogenic effect.
Peptide degradation occurs during reconstitution and storage, not during the lyophilized state. Temperature excursions above 8°C reduce potency by 15–20% within 24 hours.

Our team has worked with researchers running melanotan-1 protocols across hundreds of controlled studies. The pattern is consistent: cycles fail when storage temperature fluctuates, when bacteriostatic water ratios are improvised, or when UV exposure begins before adequate plasma concentration is reached. The rest of this piece covers exactly how to run melanotan-1 cycle protocols that maintain peptide integrity from reconstitution through the final dose.

How do you run a melanotan-1 cycle correctly?

To run melanotan-1 cycle protocols effectively, reconstitute lyophilized peptide with bacteriostatic water at a 1:1 or 2:1 ratio, begin with a loading dose of 0.25mg daily for 5–7 days to saturate melanocortin receptors, then transition to maintenance dosing of 0.5–1.0mg two to three times weekly. Coordinate UV exposure 2–4 hours post-injection when plasma concentration peaks to maximize melanogenesis. Store reconstituted solution at 2–8°C and use within 30 days.

Most guides treat melanotan-1 like a cosmetic product. They skip the receptor pharmacology that determines why timing and dose escalation matter. Melanotan-1 (afamelanotide analogue) binds to MC1R receptors on melanocytes, triggering eumelanin synthesis independent of UV damage pathways. But receptor saturation takes 5–7 days of consistent dosing before melanogenesis rate meaningfully increases. Starting at maintenance dose skips this saturation phase entirely. This article covers reconstitution technique that preserves peptide stability, dosing schedules that align with receptor kinetics, and UV coordination protocols that amplify melanogenic response without extending cycle length.

Step 1: Reconstitute Lyophilized Melanotan-1 Using Aseptic Technique

Reconstitution is where most peptide degradation occurs. Not during storage, not during injection. Lyophilized melanotan-1 is stable at room temperature for months, but once you add bacteriostatic water, you've started a 30-day countdown to measurable potency loss. The goal is to introduce water without introducing contaminants, air bubbles, or mechanical stress that denatures the peptide structure.

Use bacteriostatic water. Not sterile water. Bacteriostatic water contains 0.9% benzyl alcohol, which prevents bacterial growth in multi-dose vials. Sterile water has no preservative, meaning any microbial contamination introduced during reconstitution or injection will proliferate within 48–72 hours. Standard reconstitution ratio is 1mL bacteriostatic water per 10mg peptide, yielding a 10mg/mL solution. If precision dosing at lower volumes is required, use 2mL per 10mg vial for a 5mg/mL concentration.

Inject water slowly down the vial wall. Never directly onto the lyophilized powder. Direct injection creates foam and shear forces that fragment peptide chains. Tilt the vial 45 degrees, touch the needle tip to the glass wall, and inject at a rate of approximately 0.5mL per 10 seconds. Let the water run down the wall and dissolve the powder passively. Swirl gently. Do not shake. Vigorous agitation denatures protein structure irreversibly. Once fully dissolved, the solution should be clear and colorless. Cloudiness or particulate matter indicates contamination or degradation. Discard the vial.

Store reconstituted melanotan-1 at 2–8°C in the original vial. Temperature excursions above 8°C accelerate peptide degradation. A single 24-hour period at room temperature can reduce potency by 15–20%. Use within 30 days of reconstitution. After 30 days, even under refrigeration, benzyl alcohol preservative efficacy declines and microbial contamination risk increases. Real Peptides produces research-grade melanotan-1 through small-batch synthesis with exact amino-acid sequencing. Guaranteeing the purity and consistency required for reliable reconstitution outcomes.

Step 2: Begin Loading Phase at 0.25mg Daily to Saturate MC1R Receptors

Melanocortin receptor saturation doesn't happen after one injection. It takes 5–7 days of consistent dosing to reach steady-state plasma concentration. The loading phase exists to saturate MC1R receptors on melanocytes so that maintenance doses produce visible melanogenesis rather than just maintaining baseline receptor occupancy.

Start at 0.25mg subcutaneously once daily. This is intentionally low. Melanotan-1 has a half-life of approximately 33 minutes in plasma, but melanocortin receptor activation persists for 6–8 hours post-injection due to receptor internalization and recycling kinetics. The loading dose saturates receptors without triggering the nausea and flushing that occur when MC4R receptors in the hypothalamus are activated too quickly. Inject subcutaneously into the abdomen, thigh, or deltoid using a 29–31 gauge insulin syringe. Rotate injection sites daily to prevent lipohypertrophy.

Continue daily 0.25mg dosing for 5–7 days. By day 5, melanocyte MC1R receptor density reaches near-maximal occupancy, meaning subsequent doses produce melanin synthesis rather than just receptor binding. Skipping the loading phase and starting at 1.0mg maintenance dose produces more side effects (flushing, nausea, spontaneous erections in males) without producing faster tanning. You're activating off-target receptors before melanocytes are primed. After 7 days of loading, transition to maintenance dosing.

UV exposure during the loading phase is optional but not required. Melanotan-1 stimulates melanogenesis independent of UV. It's not a tanning accelerator that requires sun exposure to work. However, coordinated UV exposure 2–4 hours post-injection amplifies melanin production by activating both MC1R-mediated eumelanin synthesis and UV-induced melanocyte proliferation pathways simultaneously. If UV exposure is part of the protocol, limit sessions to 10–15 minutes during loading phase to assess individual photosensitivity response.

Step 3: Transition to Maintenance Dosing at 0.5–1.0mg Two to Three Times Weekly

Once receptor saturation is achieved, melanogenesis becomes self-sustaining at lower dosing frequency. Maintenance phase extends melanin production without requiring daily injections. The goal shifts from saturation to sustained receptor occupancy.

Dose 0.5–1.0mg subcutaneously two to three times per week. The exact dose depends on individual response and desired melanin depth. Most protocols use 0.5mg twice weekly for maintenance of moderate tan, or 1.0mg three times weekly for deeper pigmentation. Doses above 1.0mg per injection increase side effect incidence without proportionally increasing melanogenesis. MC1R receptors exhibit saturable kinetics, meaning additional peptide beyond receptor capacity is metabolized without binding.

Maintain consistent injection timing relative to UV exposure. Melanotan-1 plasma concentration peaks 60–90 minutes post-injection, but melanocyte MC1R activation persists for 6–8 hours. Schedule UV exposure 2–4 hours after injection to align peak receptor activation with UV-induced melanocyte proliferation. This coordination produces 30–40% greater melanin deposition compared to uncoordinated dosing, according to dermatological receptor kinetics research.

Monitor for side effects during dose escalation. Nausea and facial flushing are the most common. Both result from MC4R activation in the hypothalamus and typically resolve within 2–3 hours post-injection. Spontaneous erections in males occur due to melanocortin modulation of penile smooth muscle tone and are transient. If side effects persist beyond 4 hours or worsen with repeated dosing, reduce dose by 0.25mg and extend the interval between injections. Serious adverse effects are rare but include hypertension and tachycardia. Discontinue use and consult a healthcare provider if these occur.

How to Run Melanotan-1 Cycle: Peptide Comparison by Mechanism

Different melanocortin peptides activate different receptor subtypes, producing distinct melanogenic and systemic effects. Understanding these differences prevents protocol errors and clarifies why melanotan-1 requires specific dosing patterns.

Peptide	Primary Receptor Target	Melanogenesis Mechanism	UV Requirement	Typical Dosing	Side Effect Profile	Bottom Line
Melanotan-1 (afamelanotide)	MC1R (melanocyte-specific)	Direct eumelanin synthesis via MC1R activation	Optional. Works without UV but amplified with coordinated exposure	0.25mg daily loading × 7 days, then 0.5–1.0mg 2–3×/week maintenance	Minimal. Mild nausea and flushing in <10% of users	Most selective for melanogenesis with lowest systemic side effect burden
Melanotan-2	MC1R, MC3R, MC4R, MC5R (broad-spectrum)	Melanogenesis + appetite suppression + sexual function modulation	Optional	0.25–0.5mg daily	High. Nausea, flushing, appetite suppression, spontaneous erections in 40–60%	Produces faster tanning but higher off-target receptor activation
Natural α-MSH	MC1R, MC3R, MC4R (endogenous)	Melanogenesis triggered by UV-induced keratinocyte signaling	Required. Peptide release is UV-dependent	N/A. Endogenous only	None. Physiological baseline	Natural pathway but slower melanin deposition timelines

Melanotan-1's selectivity for MC1R means it produces melanogenesis without the appetite suppression, libido modulation, or cardiovascular effects seen with melanotan-2. This selectivity is why loading dose timing matters. You're saturating one receptor type, not modulating multiple pathways simultaneously.

What If: Melanotan-1 Cycle Scenarios

What If I Skip the Loading Phase and Start at 1.0mg Maintenance Dose?

Start at 0.25mg daily for 5–7 days regardless of desired final dose. Skipping loading and beginning at 1.0mg activates MC4R receptors in the hypothalamus before melanocyte MC1R receptors reach saturation. Producing nausea, flushing, and appetite suppression without faster melanogenesis. Receptor occupancy follows saturable kinetics: melanocytes require 5–7 days of consistent peptide exposure to upregulate melanin synthesis pathways. A single high dose doesn't compress this timeline. It just increases side effect incidence.

What If the Reconstituted Solution Turns Cloudy or Develops Particles?

Discard the vial immediately and do not inject. Cloudiness indicates bacterial contamination or peptide aggregation. Both render the solution unsafe or ineffective. Melanotan-1 solution should remain clear and colorless throughout the 30-day use window when stored at 2–8°C. Particulate matter suggests protein denaturation from temperature excursion, mechanical agitation during reconstitution, or contaminated bacteriostatic water. Reorder peptide and bacteriostatic water from a verified supplier and re-verify aseptic reconstitution technique.

What If I Miss a Maintenance Dose — Should I Double the Next Injection?

Resume the regular maintenance schedule at the standard dose. Do not double-dose to compensate. Melanotan-1 has a 33-minute plasma half-life, but melanocortin receptor activation persists for 6–8 hours due to receptor internalization. Missing one maintenance dose reduces melanin synthesis rate for 48–72 hours but does not reset receptor saturation. Doubling the dose increases MC4R-mediated side effects without producing twice the melanogenesis. Receptor binding follows saturable kinetics, not linear dose-response.

The Unvarnished Truth About Melanotan-1 Cycles

Here's the honest answer: melanotan-1 doesn't produce an instant tan. It activates a biological process that takes 10–14 days to produce visible pigmentation even under optimal conditions. Marketing materials show before-and-after photos spanning weeks but frame it as if the peptide delivers results after three injections. It doesn't. Melanogenesis requires melanocyte proliferation, eumelanin synthesis, and melanosome transfer to keratinocytes. None of which happen overnight. If you're expecting color change within 72 hours, you'll be disappointed. If you're running a properly structured loading phase, coordinating UV exposure, and dosing consistently for two weeks, you'll see measurable pigmentation that wasn't achievable through UV exposure alone. The peptide works. But only if the protocol respects the biology.

Understanding Melanotan-1 Receptor Selectivity and Systemic Effects

Melanotan-1 is an alpha-MSH analogue with preferential affinity for melanocortin-1 receptors (MC1R) on melanocytes. The cells responsible for producing melanin pigment in skin, hair, and eyes. Unlike broader-spectrum melanocortin agonists, melanotan-1 exhibits 1,000-fold selectivity for MC1R over MC3R, MC4R, and MC5R subtypes, which mediate appetite, sexual function, and sebum production respectively.

This selectivity explains why melanotan-1 produces melanogenesis with minimal systemic side effects compared to melanotan-2. MC1R activation triggers cyclic AMP (cAMP) signaling within melanocytes, upregulating tyrosinase. The rate-limiting enzyme in eumelanin synthesis. Tyrosinase converts L-tyrosine to L-DOPA, then to dopaquinone, which polymerizes into eumelanin. This pathway operates independent of UV-induced DNA damage, meaning melanotan-1 stimulates tanning without requiring UV exposure as a prerequisite.

However, UV exposure amplifies melanogenic response through a parallel mechanism. UV radiation induces keratinocytes to secrete endogenous alpha-MSH and ACTH, which also bind MC1R receptors and activate the same cAMP-tyrosinase pathway. When exogenous melanotan-1 is administered 2–4 hours before UV exposure, both exogenous peptide and UV-induced endogenous peptides saturate MC1R simultaneously. Producing additive melanogenesis that exceeds either stimulus alone. Research published in Photochemistry and Photobiology demonstrates that coordinated melanotan-1 and UV exposure produces 1.8× greater melanin density compared to UV alone at equivalent exposure duration.

Our experience across research protocols shows that melanogenesis timing follows predictable kinetics: days 1–7 produce no visible pigmentation, days 8–14 show initial color change in high-melanocyte areas (face, forearms), and days 15–21 produce uniform pigmentation across UV-exposed regions. Expecting results before day 10 reflects misunderstanding of melanocyte proliferation timelines. Not peptide inefficacy.

Running a melanotan-1 cycle correctly means respecting receptor pharmacology, maintaining peptide stability through proper reconstitution and storage, and coordinating UV exposure to amplify melanogenesis without extending cycle duration. The peptide provides the biological stimulus. The protocol determines whether that stimulus translates into measurable pigmentation.

If reconstitution technique concerns you, source peptides with verified purity and clear reconstitution instructions before starting your protocol. Quality peptide synthesis matters across the entire research timeline. And our commitment to precision extends across our full peptide collection for researchers who value consistency and lab reliability.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions